Triple Therapy Eradicated H. pylori Equally in Patients Pretreated with Omeprazole or Ranitidine

Archimandritis, Athanasios; Balatsos, V.; Delis, V.; Mentis, Αndreas; Kastanas, Konstantine; Scandalis, N

doi:10.1097/00004836-199501000-00005

Cited by 13 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found that H. pylori recurrence was the highest in medium‐ and low‐HDI countries (10.9%, 95% CI 6‐18), followed by those with a high HDI (6.2%, 95% CI 4‐8) or a very high HDI (3.1%, 95% CI 2‐4). These results are consistent with reports by Gisbert et al and Niv et al However, Ireland, Chile, Singapore, Greece, Korea, have a very high HDI and higher recurrence rates. Only one study was conducted in Singapore, with a small sample size and a short duration were included, although the results may not reflect the true recurrence rate of H. pylori in that country.…”

Section: Discussionsupporting

confidence: 93%

Systematic review with meta‐analysis: the global recurrence rate of Helicobacter pylori

Wan

et al. 2017

Aliment Pharmacol Ther

119

115

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Systematic review with meta‐analysis: the global recurrence rate of Helicobacter pylori

Wan

et al. 2017

Aliment Pharmacol Ther

119

115

View full text Add to dashboard Cite

show abstract

“…The results of our three clinical studies with omeprazole and amoxycillin regimens confirmed the findings of numerous earlier reports that H. pylori eradication significantly reduces duodenal ulcer recurrence rates 16 –65 . Among patients in the three studies who were eradicated of H. pylori after treatment, 8% (13/159) experienced a recurrence of an endoscopically confirmed duodenal ulcer within 6 months, compared to 45% (155/343) among patients who remained infected after treatment.…”

Section: Discussionsupporting

confidence: 90%

“…Forty uncontrolled studies were found to meet the inclusion criteria described in the methods section 26 –65 . The overall duodenal ulcer recurrence rates for patients who were H. pylori positive and negative at least 4 weeks after treatment are shown in Figure 2 and Table 3 for all the uncontrolled studies combined.…”

Section: Resultsmentioning

confidence: 99%

“… 12 –16 The initial observation that eradication of H. pylori resulted in a substantial decline in duodenal ulcer recurrence 16 provided the first suggestion of an infectious component in duodenal ulcer recurrence. Since then, numerous studies worldwide, using a broad range of antibacterial therapies, have confirmed the link between H. pylori eradication and reduced duodenal ulcer recurrence 17 –65 . Over the years, evidence supporting the reduction in duodenal ulcer recurrence with H. pylori eradication has been so extensive and consistent that the use of H. pylori eradication as a surrogate marker for reduced duodenal ulcer recurrence has been proposed 66 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Helicobacter pylori eradication as a surrogate marker for the reduction of duodenal ulcer recurrence

Ga¹,

Lj²,

Johnson³

et al. 1998

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Objectives: An abundance of data exists documenting the association of H. pylori eradication with the reduction in duodenal ulcer recurrence. Aim: To evaluate the validity of using H. pylori eradication as a surrogate marker for the reduction in duodenal ulcer recurrence using rigorously controlled studies. Methods: Three controlled clinical trials were conducted in patients with uncomplicated, active duodenal ulcers. Patients were treated with various combinations of omeprazole and amoxycillin. Ulcer healing and H. pylori eradication were assessed. For patients whose duodenal ulcer healed, duodenal ulcer recurrence was determined over a 6‐month period in patients with H. pylori eradication and those remaining positive for H. pylori at least 4 weeks after treatment. To support the data obtained from these clinical trials, a search of the medical literature was conducted to identify additional human clinical trials in which duodenal ulcer recurrence rates were measured and categorized by H. pylori status at least 1 month post‐treatment. Results: In 11 controlled trials, the overall 6–18‐month duodenal ulcer recurrence rate was 54% among patients remaining positive for H. pylori at least 4 weeks after treatment compared to 6% among patients with H. pylori eradication following treatment. This finding was corroborated by the uncontrolled trials, in which the duodenal ulcer recurrence rate was 64% among patients found to be H. pylori‐positive and 6% for patients found to be H. pylori‐negative at least 4 weeks after treatment. A time course of duodenal ulcer recurrence rates using pooled data from both controlled and uncontrolled studies demonstrated that duodenal ulcer recurrence rates for H. pylori‐negative patients persisted for up to 4 years following treatment. Duodenal ulcer recurrence rates for H. pylori‐positive patients increased for the first year, then levelled off. A comparison of the duodenal ulcer recurrence rates for different treatment regimens revealed that eradication regimens based on omeprazole plus antibiotics and bismuth plus antibiotics exhibited similar duodenal ulcer recurrence rates for H. pylori‐positive and ‐negative patients. Conclusion: Regardless of treatment regimens, H. pylori eradication produced a consistent and significant reduction in duodenal ulcer recurrence. Therefore H. pylori eradication, 4 weeks post‐therapy, can be used as a surrogate marker for reduced duodenal ulcer recurrence in investigational clinical trials.

show abstract

“…Side effects of this therapy were mild and well tolerated: In this and other studies, no patients dropped out . _ of the study [7]. Moreover Therefore, treating patients in remission with antibiotics can obviate maintenance therapy and also (in cases of relapse) can permit a prolonged treatment-free period.…”

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori–Positive Duodenal Ulcer: A Long‐Term Double‐Blind Randomized Study in Patients Healed with H₂‐Receptor Antagonists

Suriani

Ravizza²,

Pallante

et al. 1996

Helicobacter

View full text Add to dashboard Cite

show abstract

Triple Therapy Eradicated H. pylori Equally in Patients Pretreated with Omeprazole or Ranitidine

Cited by 13 publications

References 0 publications

Systematic review with meta‐analysis: the global recurrence rate of Helicobacter pylori

Systematic review with meta‐analysis: the global recurrence rate of Helicobacter pylori

Helicobacter pylori eradication as a surrogate marker for the reduction of duodenal ulcer recurrence

Helicobacter pylori–Positive Duodenal Ulcer: A Long‐Term Double‐Blind Randomized Study in Patients Healed with H₂‐Receptor Antagonists

Contact Info

Product

Resources

About

Triple Therapy Eradicated H. pylori Equally in Patients Pretreated with Omeprazole or Ranitidine

Cited by 13 publications

References 0 publications

Systematic review with meta‐analysis: the global recurrence rate of Helicobacter pylori

Systematic review with meta‐analysis: the global recurrence rate of Helicobacter pylori

Helicobacter pylori eradication as a surrogate marker for the reduction of duodenal ulcer recurrence

Helicobacter pylori–Positive Duodenal Ulcer: A Long‐Term Double‐Blind Randomized Study in Patients Healed with H2‐Receptor Antagonists

Contact Info

Product

Resources

About

Helicobacter pylori–Positive Duodenal Ulcer: A Long‐Term Double‐Blind Randomized Study in Patients Healed with H₂‐Receptor Antagonists